Companies → Cogent Biosciences, Inc.

Save to list

Remove

Cogent Biosciences, Inc.

United States, Waltham

Report a bug?

Claim ownership and edit

Description

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.

Industries

Wood Product Manufacturing

SIC

Lumber and Wood Products, Except Furniture

Address:

275 Wyman Street

Website:

www.cogentbio.com

Recent news:

RTW Investments Boosts Cogent Biosciences Stake in Q1 2026

RTW Investments significantly increased its position in biotech firm Cogent Biosciences in early 2026, signaling strong conviction ahead of potential regulatory milestones for its lead drug candidate.

Source: IndexBox Mar 22, 2026

Kynam Capital Reduces Cogent Biosciences Stake in Q4 2025

Analysis of Kynam Capital Management's Q4 2025 reduction in its Cogent Biosciences position, detailing the $48.38M sale and the biotech firm's current financial and clinical status.

Source: IndexBox Mar 22, 2026

Kynam Capital Reduces Viridian Therapeutics Stake by $81M in Q4 2025

Analysis of Kynam Capital Management's sale of a major portion of its Viridian Therapeutics holdings, detailing the transaction value and the company's current financial standing.

Source: IndexBox Mar 22, 2026

Kynam Capital Reduces Syndax Pharmaceuticals Stake in Q4 2025

Kynam Capital reduced its stake in cancer-focused Syndax Pharmaceuticals in late 2025, selling shares worth $8.18 million, yet the value of its remaining investment grew substantially.

Source: IndexBox Mar 21, 2026

Boone Capital Management Sells Entire Cogent Biosciences Stake in Q4 2025

Analysis of Boone Capital Management's Q4 2025 exit from Cogent Biosciences, detailing the $13.57M sale, the firm's current portfolio focus, and the market context of Cogent's performance.

Source: IndexBox Mar 20, 2026

Superstring Capital Invests $6.84M in Axsome Therapeutics in Q4 2025

Analysis of Superstring Capital Management's new $6.84 million investment in Axsome Therapeutics in late 2025, highlighting the biopharma firm's commercial portfolio and CNS focus.

Source: IndexBox Mar 18, 2026

XNAS - Delayed Quote - USD

COGT

33.38 -1.23 (-3.55%)

At close March 23 07:15 UTC

Candle

Line

Financial Statistics

Valuation Measures

Current

Quarterly

As of 06/22/2025

Market Cap: 819.77 M

Enterprise Value: 699.36 M

Trailing P/E: N/A

Forward P/E: -3.14

PEG Ratio (5yr expected): N/A

Price/Sales (ttm): N/A

Price/Book (mrq): 7.40

Enterprise Value/Revenue: N/A

Enterprise Value/EBITDA: -2.46

Financial Highlights

Profitability and Income Statement

Profit Margin: N/A%

Return on Assets (ttm): -47.45%

Return on Equity (ttm): -84.04%

Revenue (ttm): N/A

Net Income Avi to Common (ttm): -269.50 M

Diluted EPS (ttm): -1.97

Balance Sheet and Cash Flow

Total Cash (mrq): 245.66 M

Total Debt/Equity (mrq): 7.80%

Levered Free Cash Flow (ttm): -125.17 M

Disclaimer:

IndexBox is not affiliated with, associated with, or endorsed by this company in any way. The information provided on this page, including company details, is solely for informational purposes. IndexBox makes no representations or warranties about the accuracy or completeness of the information provided.

All data and information is provided “as is” for informational purposes only, and is not intended for trading purposes or financial, investment, tax, legal, accounting or other advice. Please consult your broker or financial representative to verify pricing before executing any trade. IndexBox is not an investment adviser, financial adviser or a securities broker. None of the data and information constitutes investment advice nor an offering, recommendation or solicitation by IndexBox to buy, sell or hold any security or financial product, and IndexBox makes no representation (and has no opinion) regarding the advisability or suitability of any investment.